Zuxiong Huang1, Chun Lin, Jiankai Fang, Ning Wang, Rui Zhou, Chen Pan. 1. Department of Hepatology, Affiliated Infectious Disease Hospital of Fujian Medical University, No. 312 Xihong Road, Gulou District, Fuzhou, 350025, China, huangzuxiong215@hotmail.com.
Abstract
BACKGROUND AND AIM: Acute kidney injury (AKI), as defined by the Acute Kidney Injury Network, has been widely investigated in decompensated liver cirrhosis patients. AKI is frequently progressive and independently associated with mortality in these patients. However, in the Asia-Pacific region, the majority of cases of acute-on-chronic liver failure (ACLF) are caused by acute exacerbation of chronic hepatitis B without preexisting cirrhosis. It is not clear whether these patients are at similar risk as those with underlying cirrhosis. METHODS: We performed a retrospective cohort analysis of hepatitis B-related ACLF patients in a single center from January 2004 through December 2011 and evaluated the occurrence of AKI after admission and its relation to the 3-month mortality of ACLF patients. RESULTS: A total of 439 patients with hepatitis B-related ACLF without preexisting cirrhosis were enrolled, and 158 patients (36.0%) developed AKI during hospitalization. ACLF patients with AKI had higher serum creatinine, bilirubin, and INR values and MELD scores as well as more complications compared to those without AKI (p < 0.01). The occurrence of AKI and its stage affect the 3-month mortality of ACLF patients (p < 0.001), and a greater percentage of AKI was found in non-survivors than survivors (56.7 vs. 27.6%, p < 0.001). The cumulative survival of patient with no AKI, AKI stage 1, 2 and 3 was 77.84, 65.46, 41.38 and 27.03%, respectively. CONCLUSIONS: In our study, we observed that AKI was associated with increased 3-month mortality in hepatitis B-related ACLF patients without preexisting cirrhosis. Higher AKI stage predicted a worse prognosis. Our findings support the importance of early identification and timely therapy of AKI in hepatitis B-related ACLF patients.
BACKGROUND AND AIM: Acute kidney injury (AKI), as defined by the Acute Kidney Injury Network, has been widely investigated in decompensated liver cirrhosispatients. AKI is frequently progressive and independently associated with mortality in these patients. However, in the Asia-Pacific region, the majority of cases of acute-on-chronic liver failure (ACLF) are caused by acute exacerbation of chronic hepatitis B without preexisting cirrhosis. It is not clear whether these patients are at similar risk as those with underlying cirrhosis. METHODS: We performed a retrospective cohort analysis of hepatitis B-related ACLF patients in a single center from January 2004 through December 2011 and evaluated the occurrence of AKI after admission and its relation to the 3-month mortality of ACLF patients. RESULTS: A total of 439 patients with hepatitis B-related ACLF without preexisting cirrhosis were enrolled, and 158 patients (36.0%) developed AKI during hospitalization. ACLF patients with AKI had higher serum creatinine, bilirubin, and INR values and MELD scores as well as more complications compared to those without AKI (p < 0.01). The occurrence of AKI and its stage affect the 3-month mortality of ACLF patients (p < 0.001), and a greater percentage of AKI was found in non-survivors than survivors (56.7 vs. 27.6%, p < 0.001). The cumulative survival of patient with no AKI, AKI stage 1, 2 and 3 was 77.84, 65.46, 41.38 and 27.03%, respectively. CONCLUSIONS: In our study, we observed that AKI was associated with increased 3-month mortality in hepatitis B-related ACLF patients without preexisting cirrhosis. Higher AKI stage predicted a worse prognosis. Our findings support the importance of early identification and timely therapy of AKI in hepatitis B-related ACLF patients.
Authors: Florence Wong; Jacqueline G O'Leary; K Rajender Reddy; Heather Patton; Patrick S Kamath; Michael B Fallon; Guadalupe Garcia-Tsao; Ram M Subramanian; Raza Malik; Benedict Maliakkal; Leroy R Thacker; Jasmohan S Bajaj Journal: Gastroenterology Date: 2013-08-30 Impact factor: 22.682
Authors: Justin M Belcher; Guadalupe Garcia-Tsao; Arun J Sanyal; Harjit Bhogal; Joseph K Lim; Naheed Ansari; Steven G Coca; Chirag R Parikh Journal: Hepatology Date: 2012-12-06 Impact factor: 17.425
Authors: Arun J Sanyal; Thomas Boyer; Guadalupe Garcia-Tsao; Frederick Regenstein; Lorenzo Rossaro; Beate Appenrodt; Andres Blei; Veit Gülberg; Samuel Sigal; Peter Teuber Journal: Gastroenterology Date: 2008-02-13 Impact factor: 22.682
Authors: Mitra K Nadim; John A Kellum; Andrew Davenport; Florence Wong; Connie Davis; Neesh Pannu; Ashita Tolwani; Rinaldo Bellomo; Yuri S Genyk Journal: Crit Care Date: 2012-02-09 Impact factor: 9.097
Authors: Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin Journal: Crit Care Date: 2007 Impact factor: 9.097